热门资讯> 正文
Ocular表示FDA认为第三阶段研究适合支持NDA
2024-08-07 23:31
- Shares of Ocular Therapeutix (NASDAQ:OCUL) rose 6% Wednesday after the company said the FDA has determined that its Phase 3 SOL-R clinical trial is appropriate as a registrational study to support potential approval of Axpaxli as a treatment for wet age-related macular degeneration, or wet AMD.
- Ocular said it intends to use the SOL-R and SOL-1 studies as the basis for a New Drug Application for Axpaxli for wet AMD, according to a statement.
- Earlier Wednesday, Ocular reported a flat year-over-year Q2 net loss of $0.26 per share on higher revenue of $16M. The company added that it had $459.7M in cash and equivalents as of the end of June, which should fund operations into 2028.
More on Ocular Therapeutix
- Ocular Therapeutix: A Speculative Investment For Risk-Tolerant Investors
- Investor Day Slides
- Ocular Therapeutix, Inc. (OCUL) Investor Day Call Transcript
- Ocular Therapeutix Q2 2024 Earnings Preview
- Ocular Therapeutix jumps as TD Cowen upgrades to Buy and hikes PT
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
